•
Mar 31, 2021
Evolent Health Q1 2021 Earnings Report
Evolent Health's Q1 2021 performance reflected strong revenue growth and progress in profitability initiatives.
Key Takeaways
Evolent Health reported a 29% year-over-year revenue growth excluding revenue from divested assets. The company announced four new partnerships year-to-date and saw strong operational and clinical performance. Adjusted EBITDA margin was 6.9% for Q1 2021, with $15 million in Adjusted EBITDA.
Q1 revenue grew by 29% year-over-year, excluding divested assets revenue.
Four new partnerships were announced year-to-date, progressing towards the 2021 target of 6-8.
Adjusted EBITDA margin for Q1 2021 was 6.9%, indicating progress in cost structure efforts.
Cash and cash equivalents and investments amounted to $236.2 million.